The data readout from the SEL24 Phase I/II trial in relapsed/refractory AML and the second lead asset, SEL120, moving into clinical development next year are milestones in Selvita’s internal drug R&D. This should accelerate, as the company’s plans to focus on innovation were endorsed by shareholders during the fund-raise earlier in 2018. R&D progress across the earlier-stage pipeline has been reported in several publications in recent months. The Innovations Platform conti
18 Jan 2019
Selvita - SEL120 to enter clinical development in 2019
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Selvita - SEL120 to enter clinical development in 2019
- Published:
18 Jan 2019 -
Author:
Dr Jonas Peciulis -
Pages:
20
The data readout from the SEL24 Phase I/II trial in relapsed/refractory AML and the second lead asset, SEL120, moving into clinical development next year are milestones in Selvita’s internal drug R&D. This should accelerate, as the company’s plans to focus on innovation were endorsed by shareholders during the fund-raise earlier in 2018. R&D progress across the earlier-stage pipeline has been reported in several publications in recent months. The Innovations Platform conti